NextRNA Therapeutics
Latest round
- Series A
Last raised
- Jan 2022
Total raised
- $23M
Investors
- 7
About NextRNA Therapeutics
, aka NextRNA operates as a biotechnology company that focuses on the development of RNA-targeted transformative therapies for patients with pathogenic diseases. The company was co-founded by Dominique Verhelle (CSO and interim CEO), Julia A Novina, Marc Cohen, and Leon Wert-Lamas, and in March 2022, NextRNA Therapeutics, Inc. The company develops small-molecule therapies that target human cells' non-coding RNAs, or ncRNAs (RNA molecules that are not converted into proteins), which are responsible for causing pathogenic disorders through interaction with normal protein cells. The company's medicines limit ncRNA interactions with proteins and prevent dangerous protein mutations, resulting in the treatment of a variety of diseases in the fields of neurology, oncology, and immunology.
Who invested in NextRNA Therapeutics
7 investors across 1 round
See all investors in NextRNA Therapeutics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series A
Jan 12, 2022
Amount
$23M
Investors
Questions about NextRNA Therapeutics
Who invested in NextRNA Therapeutics?
NextRNA Therapeutics has 7 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has NextRNA Therapeutics raised?
NextRNA Therapeutics has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did NextRNA Therapeutics last raise money?
NextRNA Therapeutics's most recent round on record is a Series A, in Jan 2022.
What does NextRNA Therapeutics do?
, aka NextRNA operates as a biotechnology company that focuses on the development of RNA-targeted transformative therapies for patients with pathogenic diseases.
Where is NextRNA Therapeutics headquartered?
NextRNA Therapeutics is headquartered in Cambridge, US.
Which VCs invest in companies like NextRNA Therapeutics?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at NextRNA Therapeutics's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like NextRNA Therapeutics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.